SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024.

加利福尼亚州圣克拉拉（商业新闻短讯）--HeartBeam，Inc.（纳斯达克：BEAT）是一家专注于通过为患者提供强大见解来改变心脏护理的医疗技术公司，宣布任命罗伯特·埃诺为首席执行官（CEO），自2024年10月21日（星期一）起生效。

The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work towards securing the foundational FDA 510(k) clearance for its vector-based technology and prepares for commercialization and growth..

这位经验丰富的MedTech高管于2023年1月加入HeartBeam担任总裁，并将领导公司继续努力，确保其基于载体的技术获得FDA 510（k）的基本许可，并为商业化和增长做好准备。。

As part of the long-planned transition, Branislav Vajdic, Ph.D., Founder and current CEO, will move into the role of President. In this role, Dr. Vajdic will focus on further innovating on the Company’s groundbreaking vector-based technology, driving research and development efforts, and advancing artificial intelligence (AI) applications..

作为长期计划过渡的一部分，创始人兼现任首席执行官布兰尼斯拉夫·瓦伊迪奇（BranislavVajdic）博士将出任总裁。在担任这一职务时，Vajdic博士将专注于进一步创新公司开创性的基于向量的技术，推动研发工作，并推进人工智能（AI）应用。。

“HeartBeam is at an important inflection point and the transition comes at the right time where we can best leverage the unique strengths of each leader. Branislav’s commitment to innovation and vision of providing unprecedented cardiac insights has enabled the Company to reach this pivotal point and we will continue to benefit from his drive to unlock the transformative opportunities ahead.

“HeartBeam正处于一个重要的转折点，转型恰逢其时，我们可以充分利用每位领导者的独特优势。Branislav对创新的承诺和提供前所未有的心脏洞察力的愿景，使公司能够达到这一关键点，我们将继续受益于他开启未来变革机遇的努力。

Likewise, Rob has spent his career growing companies with innovative technologies, based on his keen understanding of sales, strategic marketing and go-to-market strategies, while maximizing value for stakeholders, and I am confident that his deep experience will ensure the Company is well positioned for success,” said Rich Ferrari, Executive Chairman, Board of Directors, HeartBeam..

同样，Rob在他的职业生涯中一直致力于创新技术的发展，基于他对销售、战略营销和上市战略的敏锐理解，同时为利益相关者创造最大价值，我相信他的丰富经验将确保公司取得成功。”HeartBeam董事会执行主席Rich Ferrari说道。。

HeartBeam’s core vector-based technology captures the heart’s electrical signals from three dimensions to provide total heart intelligence. The Company’s first application of the technology is a cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG. The HeartBeam system is currently under review with the FDA.

。该公司首次应用该技术是一种无电缆、信用卡大小的设备，旨在合成12导联心电图。HeartBeam系统目前正在接受FDA的审查。

The Company has 13 issued U.S. patents and 4 issued international patents supporting the underlying technology..

该公司拥有13项已颁发的美国专利和4项已颁发的支持基础技术的国际专利。。

“The HeartBeam technology is truly transformative and stands to change how cardiac care is managed in the future. We’ve only scratched the surface of unlocking new insights and understanding how our data-rich signals can benefit physicians and patients,” commented Mr. Eno. “I am honored to lead the Company at this exciting time and look forward to my continued partnership with Branislav as we evolve our business and technology to deliver on strategic objectives.”.

Eno先生评论道：“HeartBeam技术具有真正的变革性，有望改变未来心脏护理的管理方式。我们只触及了释放新见解和了解我们的数据丰富信号如何使医生和患者受益的表面。”。“我很荣幸能在这个激动人心的时刻领导公司，并期待着在我们发展业务和技术以实现战略目标的过程中，继续与Branislav合作。”。

With over 30 years of experience, Mr. Eno, age 57, is a passionate leader who has created go-to-market strategies for multiple breakthrough products including noninvasive FFRCT for diagnosing coronary artery disease, laser cataract surgery, scanning retinal laser photocoagulation, and intravascular brachytherapy.

现年57岁的Eno先生拥有30多年的经验，是一位充满激情的领导者，他为多种突破性产品制定了上市策略，包括用于诊断冠状动脉疾病的无创FFRCT，激光白内障手术，扫描视网膜激光光凝术和血管内近距离放射治疗。

Before joining HeartBeam, Mr. Eno was Chief Executive Officer of Preview Medical, a diagnostic equipment company creating a new category of real-time, in vivo tissue classification for solid tumor cancers, using machine learning and proprietary optical signals. Previously, he was Senior Vice President of Marketing for HeartFlow, leading all aspects of the marketing and product functions for a new category of personalized, noninvasive testing for heart disease, including its initial product, HeartFlow FFRCT.

在加入HeartBeam之前，Eno先生是Preview Medical的首席执行官，Preview Medical是一家诊断设备公司，利用机器学习和专有光学信号，为实体瘤癌症创建了一种新的实时体内组织分类类别。此前，他曾任HeartFlow营销高级副总裁，领导营销和产品功能的各个方面，开发一种新的个性化无创心脏病检测类别，包括其最初的产品HeartFlow FFRCT。

He has also held senior marketing and sales leadership roles at OptiMedica, NeoGuide Systems and Avantec Vascular. Mr. Eno holds an MBA from the Stanford Graduate School of Business and a BA, with Honors and Distinction, from Stanford University, where he was Phi Beta Kappa..

他还曾在OptiMedica、NeoGuide Systems和Avantec Vascular担任高级营销和销售领导职务。Eno先生拥有斯坦福大学商学院（Stanford Graduate School of Business）的MBA学位和斯坦福大学（Stanford University）的荣誉学士学位，他曾在斯坦福大学（Stanford University）担任Phi Beta Kappa。。

About HeartBeam, Inc.

关于HeartBeam，Inc。

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions.

HeartBeam，Inc.（纳斯达克股票代码：BEAT）是一家医疗技术公司，致力于通过为患者提供强大的心脏洞察力来改变心脏护理。该公司正在创建有史以来第一个能够从三维捕获心脏电信号的无电缆12导联心电图。

This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.

该平台技术旨在用于便携式设备，可用于患者需要提供可操作心脏智能的任何地方。医生将能够识别心脏健康趋势和急性病症，并指导患者接受适当的护理-所有这些都不在医疗机构内，从而重新定义心脏健康管理的未来。

The Company holds 13 US and 4 international issued patents related to technology enablement..

该公司拥有13项美国专利和4项与技术支持相关的国际专利。。

For additional information, visit HeartBeam.com.

有关更多信息，请访问HeartBeam.com。

Forward-Looking Statements

前瞻性声明

All statements in this release that are not based on historical fact are 'forward-looking statements.' While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov.

本版本中所有不基于历史事实的声明都是“前瞻性声明”虽然管理层已将本版本中包含的任何前瞻性声明基于其当前的期望，但此类期望所依据的信息可能会发生变化。前瞻性报表涉及固有风险和不确定性，这些风险和不确定性可能导致实际结果与前瞻性报表中的结果产生重大差异，这是由于各种因素造成的，包括风险因素中描述的风险和不确定性，以及管理层对财务状况和运营结果的讨论和分析中所述的风险和不确定性。我们的10-K、10-Q表格以及其他提交给SEC的报告，可在www.SEC.gov上查阅。

We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based..

我们敦促您在评估我们的前瞻性声明时考虑这些风险和不确定性。我们提醒读者不要过度依赖任何此类前瞻性声明，因为这些声明仅在做出之日起生效。除非联邦证券法另有要求，否则我们不承担任何义务或承诺公开发布本文（或其他地方）所含任何前瞻性声明的任何更新或修订，以反映我们对其预期的任何变化或任何此类声明所依据的事件、条件或情况的任何变化。。